| 2023 | | Pharmacy Newsletter Vol.19 No.08 | 병원_부서약제팀 |
| 2023 | | Pharmacy Newsletter Vol.19 No.09 | 병원_부서약제팀 |
| 2023 | | Pharmacy Newsletter Vol.19 No.10 | 병원_부서약제팀 |
| 2023 | | Pharmacy Newsletter Vol.19 No.11 | 병원_부서약제팀 |
| 2024 | | Pharmacy Newsletter Vol.20 No.01 | 병원_부서약제팀 |
| 2021 | | Pharyngeal Airway Morphology in Skeletal Class III With Mandibular Asymmetry is Improved After Bimaxillary Orthognathic Surgery | 김영호, 신정원, 채화성 |
| 2013 | | Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). | 손영배 |
| 2019 | | Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study] | 정용식 |
| 2014 | | Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). | 정용식 |
| 2022 | | Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy | 권민석 |
| 2021 | | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study) | 강석윤 |
| 2020 | | Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07 | 안미선 |
| 2019 | | Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study | 정성현 |
| 2022 | | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) | 안미선 |
| 2016 | | Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008) | 정성현 |
| 2015 | | Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). | 안미선 |
| 2012 | | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study | 김효철 |
| 2017 | | Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | 박준성 |
| 2007 | | Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. | - |
| 2013 | | Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. | 강석윤 |
